11
UCB has been
shown to induce
regeneration of
the central nervous
system.
Umbilical cord blood
cells
improve
motor function
in experimental
systems via paracrine
signaling.
UCB contains a
rich and diverse
mixture of stem and
progenitor (source)
cells that have the
potential to generate
a variety of cell
types.
Paracrine signaling
is a form of cell-to-
cell communication in
which a cell produces
a signal to induce
changes in nearby
cells, altering the
behaviour of
those cells.
Autism spectrum disorder
Joanne Kurztberg: "Some children, who were not
speaking very much, had big increases in their
vocabulary and their functional speech. Many children
were able to attend to play and have meaningful
communication in a way that they weren't before.
Some children had less repetitive behaviours than
they did when they came onto the study."
4
Cerebral palsy
Joanne Kurztberg: "Children who received a high
dose of cord blood cells had statistically significant
changes in their motor function, more than 30%
above where they would have been predicted to be
without cord blood therapy. These children made
new connections in their brain and that's why their
function was better."
3
1 in 68 children are affected 1 in 326 children are affected
3. cerebral palsy:
1. Cellular Horizons Day 1 - Cord Blood for Treatment of Brain Injury
2. https://www.youtube.com/watch?v=1FnoZUEt6b0
3. Jessica M. Sun , Allen W. Song, Laura E. Case, Joanne Kurtzberg. Effect of Autologous Cord Blood Infusion on Motor Function and Brain Connectivity in Young Children
with Cerebral Palsy: A Randomized, Placebo-Controlled Trial. Stem Cells Translational Medicine 2017;00:000–000
4. http://www.cerebralpalsy.org/about-cerebral-palsy/definition
4. autism:
1. Cellular Horizons Day 1 - Cord Blood for Treatment of Brain Injury
2. https://www.youtube.com/watch?v=1FnoZUEt6b0
3. Geraldine Dawson, Jessica M. Sun , Katherine S. Davlantis, Joanne Kurtzberg et al. Autologous Cord Blood Infusions Are Safe and Feasible in Young Children with
Autism Spectrum Disorder: Results of a Single-Center Phase I Open-Label Trial. Stem Cells Translational Medicine 2017;6:1332–1339
